• News
  • SAN DIEGO
  • Health

BioAtla licenses antibody rights to BioMotiv

San Diego-based BioAtla announced that it licensed exclusive worldwide rights to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications to BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development.

In conjunction with the agreement, BioMotiv established Kodosil Bio, which will develop all compounds resulting from the license.

BioAtla used its proprietary comprehensive integrated antibody optimization (CIAO) platform for the identification, humanization, and optimization of the monoclonal antibody. The CIAO technology selects antibody candidates that integrate important features of manufacturing and process development into the protein design. This platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, enabling cost and time efficiencies throughout the development process.

Under the terms of the agreement, BioAtla will provide its proprietary discovery and preclinical development processes for the licensed compounds. Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept. BioAtla will receive milestone payments and royalties on sales of all potential therapeutics developed through the collaboration. If the therapeutic antibody products developed through Kodosil Bio are sublicensed or divested, BioAtla will receive a substantial portion of proceeds resulting from the action.

"We believe BioMotiv will be an ideal partner to take the antibody forward into the clinic, building on our solid discovery foundation that demonstrates the value of this antibody in the potential treatment of a variety of disease indications where there is considerable unmet need in large market opportunities," said Jay M. Short, Ph.D., president and CEO of BioAtla. "This partnership is an ideal demonstration of the power of our proprietary platform to generate unique, therapeutically-active monoclonal antibodies for a variety of diseases, both for our partners — in this case BioMotiv — and for our proprietary product portfolio."

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.